Abstract
Background: Pharmacotherapy is considered as an essential element in the treatment of schizophrenia and other psychotic disorders. Discontinuation of antipsychotic drugs increases medical use and economic burden, such as worsening of symptoms, recurrence, and hospitalization. Therefore, maintenance of drug treatment is essential to reduce the social burden caused by schizophrenia and SSP, and hence, it is important to analyze not only the incidence rate of the disorders, but also investigate the rate at which pharmacotherapy is maintained. Therefore, this study aimed to examine the current status of drug compliance using national health insurance data. Methods: This was a retrospective cohort study, which analyzed data from the nationwide insurance claims database. A total of 343,134 patients who were newly diagnosed with schizophrenia and schizophrenia similar psychosis (SSP) during 2011−2015. The adherence to antipsychotic drugs was assessed by medication possession ratio (MPR) and the risk factors of poor adherence were defined as MPR <40%.Results: The average of the MPRs among these patients was 45.8%, and the proportion of patients with less than 40% of MPR was 50.8%. It was found that female patients, the experience of “psychiatric hospital outpatient,” the experience of “psychiatric hospital admission,” the experience of “general hospital admission,” and patients receiving “medical aid” showed less risk of having statistically significant low MPR (< 40%).Conclusions: In this study, the drug adherence of schizophrenia and SSP patients currently under treatment, as estimated by MPR, was very low. However, it was also found that the MPR was high among patients receiving medical aid, with less medical expenses that they have to pay for themselves. Thus, it is possible to consider an institutional mechanism in which schizophrenia and SSP patients can be treated with less economic burden.
P3455Common electrocardiogram abnormalities confer increased mortality in patients with schizophrenia exposed to antipsychotic drugs: a register-based cohort study